News

DANIA BEACH FLORIDA, April 18, 2012. BioAxone’s Cethrin™ has been in the news. One of the treated patients was interviewed by Global TV. For the video of the interview, click here.

DANIA BEACH FLORIDA, DEC 1, 2011.  BioAxone’s Cethrin™ was named a TOP TEN  Neuroscience Project to watch. BioAxone BioSciences, Inc.  announced that the company’s lead product for treatment of acute spinal cord injury was selected by Windhover and its advisors as one of the “Top 10 Neuroscience projects to watch for 2012”.  Elsevier Business Intelligence and Windhover Conferences select companies with high-value assets for partnership, and with the potential to create future growth through investment deals. David Cassak, VP, Content, Elsevier Business Intelligence publication stated that “many of the companies we selected in the past have gone on to do big deals, and we expect the same from this year’s companies”. Windhover Conferences is an Elsevier Business Intelligence Company and a leading provider of business information and analysis for executives in the pharmaceutical and biotechnology industries. Dr. Lisa McKerracher was invited to present the program at the Windhover Therapeutic Area Conference held in Boston MA.

FORT LAUDERDALE, FL.   NOV. 21, 2011. BioAxone BioSciences Inc. was represented at the CNS Summit, Shaping the Future of Drug Development,  a conference held in Boca Raton Florida .  Dr. McKerracher presented a talk entitled “ The importance of Collaboration and Innovation in Developing Treatments for CNS Neurotrauma”.  The conference was attended by 350 professionals representing pharmaceutical and biotechnology companies, contract research manufactures and clinical investigators who had come together to focus on improving the success of bringing new treatments to patients suffering from CNS disorders. The Honorable Patrick Kennedy opened the conference that was held from Nov. 17-10, 2011.

ORLANDO, FL. September 17, 2011. Dr. McKerracher is an invited speaker attending Summit 2011  and Expo being held in Orlando Florida and organized by the Paralyzed Veterans of America (PVA). Dr. McKerracher will be presenting the clinical results from the Cethrin trial on Sunday September 18 in a talk entitled “ From bench to Phase 1/2a clinical trial in SCI”. The PVA is dedicated to a mission of research and discovery related to spinal cord dysfunction. The meeting brings together health professionals, patients and research scientists in a forum to facilitate networking and education.

FORT LAUDERDALE, FL, Aug 1, 2011. BioAxone BioSciences Inc. announced today that the company was highlighted in the July/August 2011 issue of NeuroPerspective, a publication from NI Research. BioAxone BioScience’s Founder, Dr. Lisa McKerracher commented that the attention follows the recent publication of the Cethrin clinical trial results in the May 2011 issue of Journal of Neurotrauma.

Neuroperpective  describes the efficacy results of the trial and states “even though historical control comparisons must be viewed with some skepticism, these results are striking”.

The scientific publication in Journal of Neurotrauma demonstrated that the drug was well tolerated and safe at all doses tested, and showed very interesting efficacy.  Efficacy was measured by ASIA motor score and the Cethrin-treated patients in the 3 mg cervical group showed a mean improved motor score of 27.3 points, much improved recovery compared to the expected 10 points from historical controls. The completed Cethrin trial did not have a placebo arm because it was a first-in-man Phase I/IIa safety trial in patients with motor and sensory complete spinal cord injury.

NeuroPerspective further comments that  “between preliminary evidence of impressive benefit, and Cethrin’s strong safety profile, this is an underappreciated program”.

FORT LAUDERDALE, FL, May 31, 2011. BioAxone BioSciences Inc., a Florida registered company, announced today the closing of an agreement to purchase the intellectual property and technology assets from BioAxone Therapeutic Inc., the Canadian company that developed Cethrin™. Cethrin™ is a biologic drug in development to treat acute spinal cord injury.

A  Phase 1/2a clinical trial with 48 patients enrolled at 9 sites in the United States and Canada showed promising results that indicated both safety and efficacy of Cethrin™ treatment. BioAxone BioSciences intends to move forward with a placebo-controlled Cethrin Phase 2b trial, and plans to begin enrollment in 2012.

“I am delighted to be able to announce this news” commented Dr. Lisa McKerracher, Founder and CEO of BioAxone BioSciences, and the original inventor of Cethrin™.  “The Board of Directors of  BioAxone Therapeutic, the Canadian BioAxone,  have really worked hard together  to find the best path forward to ensure continued development of Cethrin™ .  I am grateful to be given the opportunity to head the management of the program again. Placing the technology in a new company will ensure rapid progress, which is important because the preclinical and clinical data shows such promise for Cethrin™ to be the first drug to be approved to foster axon regeneration in the injured spinal cord”.

Dr. McKerracher has recruited some of the original BioAxone team members to ensure rapid progress of the program.  Dr. Dana Lasko and Dr. Patrick Frankham are working with Dr. McKerracher to re-initiate new drug manufacture, the first step towards the next clinical trial.